| Spondyloarthritis Studies and Treatments | Lifetime | 75 | TW 1 | 99.04 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 149 | TW 1 | 98.64 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 296 | TW 1 | 98.76 |
| Long-Term Effects of COVID-19 | Lifetime | 466 | TW 3 | 96.49 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 325 | TW 1 | 97.92 |
| Systemic Lupus Erythematosus Research | Lifetime | 836 | TW 4 | 97.64 |
| Gout, Hyperuricemia, Uric Acid | Lifetime | 206 | TW 4 | 95.63 |
| Zeolite Catalysis and Synthesis | Lifetime | 735 | TW 6 | 95.91 |
| Inflammasome and immune disorders | Lifetime | 813 | TW 10 | 93.69 |
| Case Reports on Hematomas | Lifetime | 134 | TW 3 | 92.08 |
| Urticaria and Related Conditions | Lifetime | 981 | TW 10 | 93.25 |
| Diffusion Coefficients in Liquids | Lifetime | 155 | TW 2 | 76.76 |
| Hidradenitis Suppurativa and Treatments | Lifetime | 952 | TW 5 | 64.93 |
| Gout, Hyperuricemia, Uric Acid | 2021-2025 | 20 | TW 1 | 97.08 |
| Long-Term Effects of COVID-19 | 2021-2025 | 314 | TW 2 | 96.74 |
| COVID-19 Clinical Research Studies | 2021-2025 | 656 | TW 3 | 97.19 |
| Diabetes Treatment and Management | 2021-2025 | 216 | TW 2 | 97.61 |
| Spondyloarthritis Studies and Treatments | 2021-2025 | 74 | TW 1 | 97.54 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 184 | TW 2 | 97.09 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 174 | TW 1 | 97.16 |
| Diabetes and associated disorders | 2021-2025 | 243 | TW 1 | 94.64 |
| Salivary Gland Disorders and Functions | 2021-2025 | 97 | TW 1 | 93.08 |
| Inflammatory mediators and NSAID effects | 2021-2025 | 65 | TW 1 | 90.85 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 233 | TW 1 | 94.57 |
| Diabetes Management and Research | 2021-2025 | 409 | TW 1 | 95.27 |
| Urticaria and Related Conditions | 2021-2025 | 146 | TW 5 | 93.79 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 232 | TW 2 | 95.12 |
| Ocular Diseases and Behçet’s Syndrome | 2021-2025 | 177 | TW 4 | 93.50 |
| Dermatology and Skin Diseases | 2021-2025 | 466 | TW 4 | 93.26 |
| Asthma and respiratory diseases | 2021-2025 | 887 | TW 5 | 92.20 |
| Endometriosis Research and Treatment | 2021-2025 | 630 | TW 4 | 88.36 |
| Inflammasome and immune disorders | 2021-2025 | 693 | TW 7 | 84.80 |
| Obstructive Sleep Apnea Research | 2021-2025 | 734 | TW 21 | 86.95 |
| Retinal and Optic Conditions | 2021-2025 | 763 | TW 13 | 86.82 |
| Cancer Risks and Factors | 2021-2025 | 451 | TW 2 | 83.93 |
| Chronic Disease Management Strategies | 2021-2025 | 927 | TW 8 | 83.59 |
| Gastrointestinal motility and disorders | 2021-2025 | 571 | TW 2 | 83.66 |
| Systemic Sclerosis and Related Diseases | 2021-2025 | 882 | TW 4 | 81.66 |
| Kawasaki Disease and Coronary Complications | 2021-2025 | 572 | TW 14 | 75.55 |
| Case Reports on Hematomas | 2021-2025 | 81 | TW 5 | 76.14 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 952 | TW 7 | 75.01 |
| Sarcoidosis and Beryllium Toxicity Research | 2021-2025 | 698 | TW 2 | 75.51 |
| Hidradenitis Suppurativa and Treatments | 2021-2025 | 261 | TW 3 | 76.50 |
| Thyroid Disorders and Treatments | 2021-2025 | 754 | TW 4 | 73.80 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | 2021-2025 | 615 | TW 3 | 68.68 |
